Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia

Anderson, E; Waller, K; Tamilarasan, AG; Lin, HY; Paramsothy, S; Leong, RW

Leong, RW (通讯作者),Concord Repatriat Gen Hosp, Concord Hosp, Dept Gastroenterol, 1A Hosp Rd, Sydney 2139, Australia.

EXPERT OPINION ON BIOLOGICAL THERAPY, 2023; 23 (8): 819

Abstract

BackgroundBiosimilar adalimumabs have improved treatment access, but without any clinical advantage, distributors rely on delivery device design-enhan......

Full Text Link